Insomnia Management in Elderly Patients

First-Line Approach: Non-Pharmacological Treatment

The American Geriatrics Society recommends cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment, demonstrating superior long-term outcomes compared to pharmacotherapy with sustained benefits up to 2 years in older adults 2, 1
CBT-I combines sleep hygiene instruction, stimulus control, sleep restriction, and cognitive restructuring, all of which have proven highly effective in elderly patients 2
Behavioral interventions provide longer-term sustained benefit compared to medications, which only offer short-term relief 3
Sleep restriction-compression therapy and multicomponent cognitive-behavioral therapy have met evidence-based criteria for efficacy in older adults 2

The American College of Cardiology is not relevant here, however, low-dose doxepin (3-6 mg) is the first-choice pharmacological agent for elderly patients, offering the best balance of efficacy and safety with fewer adverse effects than other sleep medications 1
Low-dose doxepin has demonstrated improvement in Insomnia Severity Index scores, sleep latency, total sleep time, and sleep quality in older adults with high-strength evidence 1
This medication does not carry the black box warnings or significant safety concerns associated with benzodiazepines and Z-drugs 1
Doxepin is particularly effective for sleep maintenance insomnia, which is the predominant complaint in elderly patients 3, 4
Start at the lowest available dose (3 mg) due to altered pharmacokinetics and increased sensitivity to side effects in this age group 1

Suvorexant (orexin receptor antagonist) is effective for sleep maintenance insomnia with moderate-quality evidence showing improvement in total sleep time and wake after sleep onset in older populations 1, 4
Ramelteon (8 mg) has demonstrated efficacy in reducing sleep onset latency in older adults, though with lower quality evidence for adverse effects 1, 4
Zaleplon (5 mg in elderly) may be considered specifically for sleep-onset insomnia at reduced doses 1, 4

The American Geriatrics Society specifically recommends against the use of benzodiazepines in elderly patients due to substantial risks that outweigh any benefits 1
Trazodone should not be used despite its frequent off-label prescription, with limited efficacy evidence and unfavorable adverse effect profile 1
The American Academy of Sleep Medicine explicitly does not recommend trazodone for sleep onset or maintenance insomnia 4
Over-the-counter antihistamines (including diphenhydramine) must be avoided due to antimuscarinic effects, rapid tolerance development, and risk of daytime sedation and delirium 1, 4

Review all current medications for sleep-disrupting agents: β-blockers, bronchodilators, corticosteroids, decongestants, diuretics, SSRIs, and SNRIs all contribute to insomnia 2, 5
Assess for underlying medical conditions: cardiac disease, pulmonary disease, pain from osteoarthritis, nocturia, and neurologic deficits are common contributors to insomnia in this age group 2, 5
Screen for depression: untreated insomnia is a risk factor for new onset depression, and depression commonly presents with insomnia in elderly patients 5
Evaluate sleep hygiene: frequent daytime napping, excessive time in bed, insufficient daytime activities, and late evening exercise all impair sleep 6

Limit pharmacological therapy to short-term use when possible (typically less than 4 weeks for acute insomnia) 4
Monitor closely for adverse effects including next-day impairment, falls, confusion, and behavioral abnormalities 1
Combine medication with behavioral interventions for optimal outcomes, as combination therapy provides better results than either modality alone 3